Athira Pharma Announces Publication in Journal of Alzheimer’s Disease Highlighting Need for Novel Alzheimer’s Disease Treatment Approaches and Potential of Enhancing HGF/MET Pathway
01 févr. 2023 07h00 HE
|
Athira Pharma, Inc.
BOTHELL, Wash., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal...
AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial
26 janv. 2023 07h00 HE
|
AC Immune SA
AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial ACI-24.060 elicited an anti-Abeta antibody response...
AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer’s Disease
18 janv. 2023 07h00 HE
|
AC Immune SA
AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer’s Disease First Alzheimer’s patient imaged with PI-2620 in ADvance, the pivotal Phase 3...
Global Alzheimer’s Platform Foundation Statement on FDA Accelerated Approval of Lecanemab
06 janv. 2023 14h25 HE
|
Global Alzheimer's Platform Foundation
Washington, D.C., Jan. 06, 2023 (GLOBE NEWSWIRE) -- "We applaud the Food and Drug Administration (FDA)’s decision to grant accelerated approval to lecanemab, a treatment that offers millions of...
Athira Pharma Provides 2023 Pipeline Outlook
05 janv. 2023 07h00 HE
|
Athira Pharma, Inc.
Advancing small molecule therapeutic candidates with clinical and preclinical data suggesting potential neuroprotective, neurotrophic, procognitive and disease-modifying effects Fosgonimeton Phase...
IGC Applauds Signing of Bipartisan Medical Marijuana and Cannabidiol Research Expansion Act
07 déc. 2022 08h30 HE
|
INDIA GLOBALIZATION CAPITAL INC.
POTOMAC, Md., Dec. 07, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- India Globalization Capital, Inc (NYSE American: IGC) (“IGC” or the “Company”), applauds the signing of the Medical Marijuana and...
Athira Pharma to Host Virtual R&D Event on December 7, 2022, from 2:00 –3:30 pm Eastern time
01 déc. 2022 07h00 HE
|
Athira Pharma, Inc.
BOTHELL, Wash., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development
30 nov. 2022 07h00 HE
|
AC Immune SA
AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development Data presented at CTAD 2022 confirm excellent clinical performance of ACI-35.030 vaccine candidateBased...
Athira Pharma Highlights Therapeutic Potential of Fosgonimeton in Presentation of Additional Biomarker Data in Mild-to-Moderate Alzheimer’s Disease Patients from ACT-AD Phase 2 Study at CTAD Conference
29 nov. 2022 11h00 HE
|
Athira Pharma, Inc.
Fosgonimeton treatment-related reductions in biomarkers of neurodegeneration (NfL) and neuroinflammation (GFAP) significantly correlated with improvements in clinical outcomes as assessed by the GST,...
AC Immune to Present Progress of Alzheimer’s Disease Programs targeting Abeta and Tau at the 15th CTAD Conference
23 nov. 2022 07h30 HE
|
AC Immune SA
Next generation SupraAntigen® liposomal vaccine platform augments immunization against pathological targets of Alzheimer’s diseaseNew data on anti-phospho-Tau vaccines confirm safety, tolerability and...